Trial Profile
Safety, Tolerability, and Efficacy of Simeprevir 150 mg Daily Plus Sofosbuvir 400 mg Daily for 24 Weeks in Patients With Chronic Hepatitis C Genotype 1 With CPT Score of 6 or Lower Who Are IFN-Intolerant or Unwilling to be Treated With IFN
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 18 Oct 2016
Price :
$35
*
At a glance
- Drugs Simeprevir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 12 Oct 2016 Planned End Date changed from 1 Oct 2017 to 1 Jan 2016.
- 12 Oct 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Jan 2016.
- 12 Oct 2016 Planned initiation date changed from 1 Oct 2015 to 1 Sep 2015.